Novartis Ag

University of Pennsylvania

I-mab Biopharma US Limited

I-mab

Harbour Biomed (shanghai) Co., Ltd.

I-mab Biopharma (hangzhou) Co., Ltd.

Yongqiang Wang

Qilong Wu

Michael C Milone

Jennifer Brogdon

Mark Knapp

David Jonathan Glass

Joan Mannick

Leon Murphy

Fangmin Xu

Elisabetta Traggiai

Zorica Dragic

Johanna Abend

Danqing Wu

Adam Lloyd Feire

Steven Kovacs

Lichun Wang

Marco Ruella

Carl H June

Hilmar Erhard Ebersbach

Jiquan Zhang

Andreas Loew

Lei Fang

Saar Gill

David L Porter

Jingwu Zang

Bingshi Guo

Zhengyi Wang

Reshma Singh

Celeste Richardson

Saad Kenderian

Heather Huet

Eugene Choi

Gabriela Plesa

Wenqing Jiang

Yun Zhang

Thomas Huber

Fei Chen

Huijuan Song

Avery D Posey

Lai Wei

Qiumei Yang

Julia Jascur

Yi Ding

Jihyun Lee

Chuchu Zhao

Ming-jin Jheng

Yunxing Yang

Yuetao Wu

Beibei Qin

The present invention discloses CLDN18.2-targeting antibodies, bispecific antibodies and use thereof. The CLDN18.2-targeting antibody is a single-domain heavy-chain antibody that has high affinity for tumor cells endogenously expressing CLDN18.2 and can induce high endocytic activity. The bispecific antibody can target CLDN18.2 and CD3 and retains the binding effect of an Fc to an FcRn; meanwhile, a mutant Fc is preferred so as to reduce the binding to an FcgR and thus the activation of non-specific T cells caused by the cross-linking of an FcgR. The CD3-terminus activity is optimized so that the release of common cytokines in CRS, such as IL6 and TNFα can be reduced.

CLDN18.2-targeting antibody, bispecific antibody and use thereof

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Polyomavirus neutralizing antibodies

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Treatment of cancer using a CD123 chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

Anti-LAG-3 antibodies and uses thereof

Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Anti-PD-L1 antibodies and uses thereof

Anti-BCMA chimeric antigen receptor

The present disclosure is directed to anti-VP1 antibodies, antibody fragments, and their uses for the reducing the likelihood or treatment of polyoma virus infection.

Growing community of inventors

Shanghai, China

Yongqiang Wang